No image available

Eoin O'Connell

Principal Data Scientist

Eoin has worked as a data scientist, consultant, and statistician in a range of industries. Prior to joining A&O, he was at the Department of Justice & Equality in Ireland providing high-level civil servants with insights on the flow of people through the criminal justice system. Before that, he was a researcher alongside cardiologists across several hospitals in Dublin, quantifying risk factors and prognoses for patients with cardiovascular disease. He has also worked in the fields of chemical exposure modelling, nutrition & physical exercise, financial services, and consulted on many standalone research and engineering projects – from diagnosing pneumonia in Malawian infants to monitoring stock for a Spanish clothing conglomerate.He joined A&O in 2019 and works with lawyers across our practice groups, using data science techniques to increase the efficiency through which we deliver client projects, typically managing the large-scale extraction, processing, enrichment, and summarisation of data, as well as providing expert advice on technical issues.

Published Work

-     Arundell, L, Salmon, J, Veitch, J, O’Connell, E, et al. Standardising the ‘after-school’ period for children’s physical activity and sedentary behaviour. Health Promotion Journal of Australia, 2013. -     Bermingham, M, Shanahan, MK, O’Connell, E, et al. Aspirin Use In Heart Failure: Is Low Dose Therapy Associated With Mortality And Morbidity Benefits In A Large Community Population? Circulation: Heart Failure, 2014. -     Hinkley, T, O’Connell, E, Okely, T, et al. Assessing volume of accelerometry data for reliability in preschool children. Medicine & Science in Sports and Exercise, 2012. -     Hume, C, Salmon, J, Veitch, J, O’Connell, E, et al. Socio-demographic characteristics of children experiencing socioeconomic disadvantage who meet physical activity and screen-time recommendations: The READI study. Preventive Medicine, 2011. -     Ledwidge, M, Gallagher, J, Conlon, C, Tallon, E, O’Connell, E, et al. Natriuretic Peptide-Based Screening and Collaborative Care for Heart Failure: The STOP-HF Randomized Trial. The Journal of the American Medical Association, 2013. -     McClelland, S, Zhou, S, O’Connell, E, et al. New-onset heart failure in the STOP-HF programme. Natriuretic peptide defines and tracks risk and enables earlier diagnosis of heart failure. European Journal of Heart Failure, 2020. -     McDonald, K, Glezeva, N, Collier, P, O’Reilly, J, O’Connell, E, et al. Tetranectin, a potential novel diagnostic biomarker of heart failure, is expressed within the myocardium and associates with cardiac fibrosis. Scientific Reports, 2020. -     O’Connell, E. Various articles in: Greenwald, SJ & Thomley, JE (Eds.) The Encyclopedia of Mathematics and Society, 2011. -     Pharithi, RB, Ferre-Vallverdu, M, Maisel, AS, O'Connell, E, et al. Sacubitril-Valsartan in a routine community population: attention to volume status critical to achieving target dose. European Society of Cardiology: Heart Failure, 2020. -     Ridgers, ND, Salmon, J, Ridley, K, O’Connell, E, et al. Agreement between activPAL and ActiGraph for assessing children’s sedentary time. International Journal of Behavioral Nutrition and Physical Activity, 2012. -     Watson, CJ, James, S. O’Connell, E, et al. Influence of diabetes on natriuretic peptide thresholds in screening for Stage B heart failure. Biomarkers, 2016. -     Watson, CJ, Tea, I, O'Connell, E, et al. Comparison of longitudinal change in sST2 vs BNP to predict major adverse cardiovascular events in asymptomatic patients in the community. Journal of Cellular and Molecular Medicine, 2020.



-     Certificate in Financial Mathematics, Institute and Faculty of Actuaries, 2014. -     MLitt in Experimental Psychology awarded with distinction, University College Dublin, 2005. -     BA(Hons.) in Psychology, University College Dublin, 2003.
A&O Shearman was formed on May 1, 2024 by the combination of Shearman & Sterling LLP and Allen & Overy LLP and their respective affiliates (the legacy firms). Any matters referred to above may include matters undertaken by one or more of the legacy firms rather than A&O Shearman.